Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Ikena Oncology Inc (IKNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: IKNA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.33% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 65.63M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 2 | Beta 0.45 | 52 Weeks Range 0.97 - 1.94 | Updated Date 06/30/2025 |
52 Weeks Range 0.97 - 1.94 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Earnings Date
Report Date 2025-06-06 | When Before Market | Estimate -0.41 | Actual -0.1489 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.87% | Return on Equity (TTM) -30.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -42292551 | Price to Sales(TTM) 43.56 |
Enterprise Value -42292551 | Price to Sales(TTM) 43.56 | ||
Enterprise Value to Revenue 0.93 | Enterprise Value to EBITDA -0.54 | Shares Outstanding 48258100 | Shares Floating 6112372 |
Shares Outstanding 48258100 | Shares Floating 6112372 | ||
Percent Insiders 8 | Percent Institutions 81.52 |
Analyst Ratings
Rating 2 | Target Price 2 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ikena Oncology Inc
Company Overview
History and Background
Ikena Oncology, Inc. is a clinical-stage biotechnology company focused on developing targeted oncology therapies that address key signaling pathways that drive cancer progression. Founded in 2016, it has grown through internal development and strategic partnerships to advance its pipeline.
Core Business Areas
- Targeted Oncology Therapies: Developing and commercializing small molecule therapeutics targeting specific signaling pathways and proteins involved in cancer development and progression. The therapeutic areas include areas such as MAPK pathway, Hippo Pathway, and RAS pathway.
Leadership and Structure
The leadership team includes experienced executives in drug development and commercialization. The organizational structure typically involves research, clinical development, regulatory affairs, and commercial teams.
Top Products and Market Share
Key Offerings
- IK-930 (TEAD inhibitor): A TEAD inhibitor designed to block the activity of the TEAD transcription factors in the Hippo signaling pathway. Currently in clinical trials for various solid tumors. Market share is currently 0 as it is still in clinical trials. Competitors include companies working on similar Hippo pathway modulators. Key competitors are larger pharmaceutical companies with deep oncology pipelines.
- IK-595 (RAS-targeted program): A program designed to target the RAS signaling pathway, which is frequently mutated in cancer. Currently in preclinical and early clinical development. Market share is currently 0 as it is still in preclinical development. Competitors include companies working on similar RAS pathway inhibitors or downstream effectors.
Market Dynamics
Industry Overview
The oncology therapeutics market is highly competitive and rapidly evolving, with significant investment in targeted therapies and immunotherapies. There's a growing emphasis on personalized medicine and biomarker-driven drug development.
Positioning
Ikena Oncology Inc is positioned as a targeted oncology company focusing on specific signaling pathways. Its competitive advantage lies in its novel drug candidates and its focus on addressing unmet medical needs in cancer treatment.
Total Addressable Market (TAM)
The oncology market is estimated to be worth hundreds of billions of dollars globally. Ikena Oncology Inc is positioned within this TAM by targeting specific pathways within specific cancer types.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting key cancer signaling pathways
- Experienced leadership team
- Strong focus on biomarker-driven drug development
- Strategic partnerships with research institutions and pharmaceutical companies
Weaknesses
- Limited revenue stream as a clinical-stage company
- Dependence on clinical trial success
- High cash burn rate
- Competition from larger pharmaceutical companies
Opportunities
- Successful clinical trial outcomes
- Potential for strategic partnerships and collaborations
- Expansion into new cancer indications
- Advancements in biomarker technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other targeted therapies
- Patent expirations
Competitors and Market Share
Key Competitors
- MRTX
- DEEP
- GILD
- LLY
Competitive Landscape
Ikena Oncology Inc competes with larger pharmaceutical and biotechnology companies in the oncology space. Its advantage lies in its targeted approach and novel drug candidates, but it faces the challenges of limited resources and dependence on clinical trial success.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancing drug candidates through preclinical and clinical development stages.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst projections vary depending on the perceived likelihood of success for their pipeline programs.
Recent Initiatives: Recent initiatives include progressing IK-930 and IK-595 through clinical trials, presenting data at scientific conferences, and securing financing to fund operations.
Summary
Ikena Oncology Inc. is a clinical-stage company with promising targeted oncology therapies, particularly IK-930, and IK-595. While still early in its trajectory, successful clinical trials could significantly enhance its value. Its main challenges are its high cash burn rate and competition from larger, more established pharmaceutical companies. The company's focus on biomarker-driven development could provide a competitive advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Ikena Oncology Inc. investor relations website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on your own due diligence and consultation with a qualified financial advisor. Market share data are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ikena Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-03-26 | President, CEO & Director Dr. Mark Manfredi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://ikenaoncology.com |
Full time employees 9 | Website https://ikenaoncology.com | ||
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.